Bristol Financial Statements From 2010 to 2024

BMY Stock  USD 48.86  0.13  0.27%   
Bristol Myers financial statements provide useful quarterly and yearly information to potential Bristol Myers Squibb investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Bristol Myers financial statements helps investors assess Bristol Myers' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Bristol Myers' valuation are summarized below:
Gross Profit
36.4 B
Profit Margin
0.1783
Market Capitalization
99.3 B
Enterprise Value Revenue
2.8226
Revenue
45 B
We have found one hundred twenty available fundamental signals for Bristol Myers Squibb, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Bristol Myers Squibb prevailing market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 108.4 B in 2024. Enterprise Value is likely to rise to about 112.4 B in 2024

Bristol Myers Total Revenue

47.26 Billion

Check Bristol Myers financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bristol main balance sheet or income statement drivers, such as Depreciation And Amortization of 10.2 B, Interest Expense of 1.2 B or Selling General Administrative of 3.6 B, as well as many exotic indicators such as Price To Sales Ratio of 2.98, Dividend Yield of 0.0374 or PTB Ratio of 6.92. Bristol financial statements analysis is a perfect complement when working with Bristol Myers Valuation or Volatility modules.
  
This module can also supplement Bristol Myers' financial leverage analysis and stock options assessment as well as various Bristol Myers Technical models . Check out the analysis of Bristol Myers Correlation against competitors.

Bristol Myers Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets99.9 B95.2 B60.5 B
Slightly volatile
Short and Long Term Debt Total43.5 B41.5 B21.9 B
Slightly volatile
Total Current Liabilities23.4 B22.3 B12.9 B
Slightly volatile
Total Stockholder Equity15 B29.4 B21.4 B
Slightly volatile
Property Plant And Equipment Net5.2 BB5.4 B
Slightly volatile
Retained Earnings22 B28.8 B28.1 B
Very volatile
Cash12 B11.5 B7.4 B
Slightly volatile
Non Current Assets Total66.6 B63.4 B40.8 B
Slightly volatile
Cash And Short Term Investments12.9 B12.3 BB
Slightly volatile
Net Receivables16 B15.3 B7.4 B
Slightly volatile
Good Will22.2 B21.2 B12.2 B
Slightly volatile
Common Stock Shares Outstanding1.6 B2.1 B1.8 B
Pretty Stable
Liabilities And Stockholders Equity99.9 B95.2 B61.3 B
Slightly volatile
Non Current Liabilities Total45.6 B43.4 B25.8 B
Slightly volatile
Inventory1.9 B2.7 B1.8 B
Slightly volatile
Other Current Assets1.8 B1.5 B2.4 B
Slightly volatile
Total Liabilities69 B65.7 B38.7 B
Slightly volatile
Property Plant And Equipment Gross13.5 B12.8 B6.8 B
Slightly volatile
Total Current Assets33.4 B31.8 B19.8 B
Slightly volatile
Short Term Debt3.4 B3.3 B1.9 B
Slightly volatile
Intangible Assets28.9 B27.5 B18.3 B
Slightly volatile
Accounts Payable1.9 B3.3 B2.3 B
Slightly volatile
Common Stock Total Equity255.5 M335.8 M249.7 M
Slightly volatile
Short Term Investments775.2 M816 M1.6 B
Very volatile
Capital Stock258.1 M335.8 M249.9 M
Slightly volatile
Common Stock258.1 M335.8 M249.9 M
Slightly volatile
Other Liabilities4.9 B8.5 B6.2 B
Slightly volatile
Other Assets3.3 B3.3 BB
Slightly volatile
Long Term Debt38.5 B36.7 B19.7 B
Slightly volatile
Property Plant Equipment5.8 B7.2 B5.3 B
Slightly volatile
Current Deferred Revenue4.4 B4.2 B2.1 B
Slightly volatile
Retained Earnings Total Equity24.5 B23 B29.7 B
Slightly volatile
Long Term Debt Total42.3 B40.3 B20.5 B
Slightly volatile
Capital Surpluse54.5 B51.9 B20.3 B
Slightly volatile
Deferred Long Term Liabilities2.2 B2.5 B2.2 B
Slightly volatile
Long Term InvestmentsB2.1 B2.5 B
Slightly volatile
Non Current Liabilities Other376.2 M396 M3.9 B
Pretty Stable
Deferred Long Term Asset Charges557.2 M586.5 M1.1 B
Pretty Stable
Short and Long Term Debt2.9 B3.1 B4.7 B
Slightly volatile
Cash And Equivalents10.5 B10.5 B7.5 B
Slightly volatile
Net Invested Capital70.4 B69.2 B43.8 B
Slightly volatile
Net Working Capital9.5 B9.5 B7.1 B
Slightly volatile
Capital Lease Obligations1.3 B1.7 B965.6 M
Slightly volatile

Bristol Myers Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization10.2 B9.8 B3.7 B
Slightly volatile
Selling General Administrative3.6 B6.4 B3.5 B
Slightly volatile
Total Revenue47.3 B45 B27.4 B
Slightly volatile
Gross Profit36 B34.3 B20.5 B
Slightly volatile
Other Operating Expenses38.7 B36.8 B22.5 B
Slightly volatile
Operating Income18.1 B17.2 B6.5 B
Slightly volatile
EBIT5.1 B9.4 B5.2 B
Slightly volatile
EBITDA20.1 B19.2 B9.3 B
Slightly volatile
Cost Of Revenue5.8 B10.7 B6.6 B
Slightly volatile
Total Operating Expenses27.4 B26.1 B15.5 B
Slightly volatile
Research Development9.8 B9.3 B6.5 B
Slightly volatile
Selling And Marketing Expenses1.3 B1.4 B4.5 B
Pretty Stable
Discontinued OperationsB6.7 B7.3 B
Slightly volatile
Non Recurring2.2 B2.1 B1.6 B
Slightly volatile
Tax Provision305.9 M322 M1.1 B
Pretty Stable
Interest Income2.2 B2.1 B497.3 M
Slightly volatile
Reconciled Depreciation6.8 B9.8 B3.7 B
Slightly volatile

Bristol Myers Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Free Cash Flow13.3 B12.7 B6.8 B
Slightly volatile
Begin Period Cash Flow4.8 B9.3 B6.6 B
Slightly volatile
Depreciation10.2 B9.8 B3.9 B
Slightly volatile
Dividends Paid2.5 B4.7 B2.9 B
Slightly volatile
Capital Expenditures837.5 M1.2 B820 M
Slightly volatile
Total Cash From Operating Activities14.6 B13.9 B7.7 B
Slightly volatile
End Period Cash Flow12.1 B11.5 B7.4 B
Slightly volatile
Stock Based Compensation262.8 M518 M367.3 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.982.35883.9928
Slightly volatile
Dividend Yield0.03740.04470.0305
Pretty Stable
PTB Ratio6.923.60725.2268
Very volatile
Days Sales Outstanding13012492.9936
Slightly volatile
Book Value Per Share14.9414.224311.9242
Slightly volatile
Free Cash Flow Yield0.130.11920.0667
Slightly volatile
Invested Capital1.481.40890.7968
Slightly volatile
Operating Cash Flow Per Share7.036.69893.9598
Slightly volatile
Stock Based Compensation To Revenue0.01280.01150.0165
Slightly volatile
PB Ratio6.923.60725.2268
Very volatile
EV To Sales3.113.02544.3553
Pretty Stable
Free Cash Flow Per Share6.426.11453.5011
Slightly volatile
ROIC0.230.23170.1356
Very volatile
Inventory Turnover2.544.01693.7191
Slightly volatile
Days Of Inventory On Hand14490.866109
Pretty Stable
Payables Turnover3.813.28113.0585
Slightly volatile
Sales General And Administrative To Revenue0.180.160.1036
Slightly volatile
Research And Ddevelopement To Revenue0.140.20660.2319
Very volatile
Cash Per Share6.235.93524.761
Slightly volatile
POCF Ratio7.287.659519.2405
Slightly volatile
Interest Coverage20.3414.787316.4207
Slightly volatile
PFCF Ratio8.818.391527.422
Slightly volatile
Days Payables Outstanding91.58111131
Slightly volatile
EV To Operating Cash Flow9.339.82420.72
Slightly volatile
EV To Free Cash Flow11.310.762829.2209
Slightly volatile
Intangibles To Total Assets0.540.51130.4152
Slightly volatile
Current Ratio1.961.42711.8451
Very volatile
Receivables Turnover5.62.94854.3308
Slightly volatile
Graham Number36.9935.232923.9857
Slightly volatile
Shareholders Equity Per Share14.9414.224311.9242
Slightly volatile
Debt To Equity1.481.40890.7968
Slightly volatile
Revenue Per Share22.8421.752514.3636
Slightly volatile
Interest Debt Per Share21.6320.604211.3911
Slightly volatile
Debt To Assets0.460.43570.319
Slightly volatile
Enterprise Value Over EBITDA12.227.100218.7409
Slightly volatile
Short Term Coverage Ratios4.014.22437.8081
Slightly volatile
Operating Cycle226215199
Very volatile
Price Book Value Ratio6.923.60725.2268
Very volatile
Days Of Payables Outstanding91.58111131
Slightly volatile
Price To Operating Cash Flows Ratio7.287.659519.2405
Slightly volatile
Price To Free Cash Flows Ratio8.818.391527.422
Slightly volatile
Operating Profit Margin0.250.38310.2102
Pretty Stable
Company Equity Multiplier1.833.23342.3933
Slightly volatile
Long Term Debt To Capitalization0.590.56470.386
Slightly volatile
Total Debt To Capitalization0.610.58490.4116
Slightly volatile
Return On Capital Employed0.290.23650.1807
Very volatile
Debt Equity Ratio1.481.40890.7968
Slightly volatile
Ebit Per Revenue0.250.38310.2102
Pretty Stable
Quick Ratio1.11.23731.7176
Very volatile
Dividend Paid And Capex Coverage Ratio3.393.92083.468
Very volatile
Net Income Per E B T0.640.95080.7701
Pretty Stable
Cash Ratio0.50.5150.7934
Very volatile
Operating Cash Flow Sales Ratio0.170.3080.246
Slightly volatile
Days Of Inventory Outstanding14490.866109
Pretty Stable
Days Of Sales Outstanding13012492.9936
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.610.91280.8031
Pretty Stable
Cash Flow Coverage Ratios0.320.33430.5924
Slightly volatile
Price To Book Ratio6.923.60725.2268
Very volatile
Fixed Asset Turnover3.255.60054.5042
Slightly volatile
Price Cash Flow Ratio7.287.659519.2405
Slightly volatile
Enterprise Value Multiple12.227.100218.7409
Slightly volatile
Debt Ratio0.460.43570.319
Slightly volatile
Cash Flow To Debt Ratio0.320.33430.5924
Slightly volatile
Price Sales Ratio2.982.35883.9928
Slightly volatile
Asset Turnover0.880.4730.6456
Very volatile
Gross Profit Margin0.80.76240.7421
Slightly volatile
Price Fair Value6.923.60725.2268
Very volatile

Bristol Myers Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap108.4 B103.2 B100 B
Slightly volatile
Enterprise Value112.4 B107.1 B104.2 B
Slightly volatile

Bristol Fundamental Market Drivers

Forward Price Earnings6.93
Cash And Short Term Investments12.3 B

Bristol Upcoming Events

2nd of February 2024
Upcoming Quarterly Report
View
25th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
2nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Bristol Myers Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Bristol Myers income statement, its balance sheet, and the statement of cash flows. Bristol Myers investors use historical funamental indicators, such as Bristol Myers's revenue or net income, to determine how well the company is positioned to perform in the future. Although Bristol Myers investors may use each financial statement separately, they are all related. The changes in Bristol Myers's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Bristol Myers's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Bristol Myers Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Bristol Myers. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue4.2 B4.4 B
Total Revenue45 B47.3 B
Cost Of Revenue10.7 B5.8 B
Stock Based Compensation To Revenue 0.01  0.01 
Sales General And Administrative To Revenue 0.16  0.18 
Research And Ddevelopement To Revenue 0.21  0.14 
Capex To Revenue(0.03)(0.03)
Revenue Per Share 21.75  22.84 
Ebit Per Revenue 0.38  0.25 

Pair Trading with Bristol Myers

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol Myers position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myers will appreciate offsetting losses from the drop in the long position's value.

Moving together with Bristol Stock

  0.62VKTX Viking Therapeutics Potential GrowthPairCorr

Moving against Bristol Stock

  0.48ZURA Zura Bio Limited Financial Report 10th of May 2024 PairCorr
The ability to find closely correlated positions to Bristol Myers could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bristol Myers when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bristol Myers - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bristol Myers Squibb to buy it.
The correlation of Bristol Myers is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bristol Myers moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bristol Myers Squibb moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bristol Myers can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Bristol Myers Squibb offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bristol Myers' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bristol Myers Squibb Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bristol Myers Squibb Stock:
Check out the analysis of Bristol Myers Correlation against competitors.
You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Bristol Stock analysis

When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Is Bristol Myers' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myers. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myers listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.09)
Dividend Share
2.31
Earnings Share
3.86
Revenue Per Share
21.753
Quarterly Revenue Growth
0.006
The market value of Bristol Myers Squibb is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myers' value that differs from its market value or its book value, called intrinsic value, which is Bristol Myers' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myers' market value can be influenced by many factors that don't directly affect Bristol Myers' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol Myers' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bristol Myers is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myers' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.